Ranibizumab SR is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Macular Edema. According to GlobalData, Phase III drugs for Macular Edema have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ranibizumab SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ranibizumab SR overview

Ranibizumab (Susvimo) is a humanized monoclonal antibody fragment and a recombinant humanized IgO 1 isotype. It is formulated as an solution for intravitreal route of administration via ocular implant. Lucentis is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication.

Susvimo (Ranibizumab port delivery system (RPDS) implant) is under development for the treatment of wet neovascular age-related macular degeneration, diabetic retinopathy and macular edema secondary to retinal vein occlusion (CRVO and BRVO), diabetic macular edema. It is a sustained release delivery formulation. The drug candidate is administered through implantation. It acts by targeting vascular endothelial growth factor (VEGF-A). The drug candidate is based on ForSight VISION4 PDS technology. The drug candidate is a new molecular entity.

F. Hoffmann-La Roche overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

For a complete picture of Ranibizumab SR’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.